introduction: Crimean-Congo hemorrhagic fever (CCHF), an acute viral disease in humans, is characterized by extensive ecchymoses, bleeding, and hepatic dysfunction and is associated with a 30% case-fatality ratio. We describe the clinical, and laboratory findings and the role of supportive and antiviral therapy for 2 patients who received a diagnosis of Crimean- Congo hemorrhagic fever (CCHF).
The patients had immunoglobulin M antibodies results positive for CCHF virus in blood. One of the patients was considered to have severe case of CCHF with clinical picture of fever, headache, abdominal pain, myalgia, drowsiness, epistaxis, hematemesis, and hepatitis. One of the patients was given ribavirin, and both survived.
Conclusion: We suggest using ribavirin to treat patients, particularly those with severe cases.